How long can the American customer love myth of high growth last? | Insight Research
Despite 3 consecutive years of high performance growth, market concerns about Aimeike's future growth momentum have not been resolved.
Before Brother Yang spoke out, Shierjia was already “held hostage” by the channel
Going public is the pinnacle.
Behind the slowdown in Aimeike's growth rate in the 3rd quarter: “Women's Maotai” can't handle the slump in consumption?
Demand weakens
GLP-1 drugs have become a stock price code: Why did Changshan Pharmaceutical, which has no weight loss tests and no disclosure of efficacy data, take off?
As a rising star in the weight loss industry, glucosane-like peptide-1 receptor (“GLP-1”) drugs are stirring up the stock prices of pharmaceutical companies that have been dormant for a long time. On September 26, Changshan Pharmaceutical (300255.SZ) issued the “Notice on Abnormal Stock Trading Fluctuations”, which emphasized that the clinical trial indications of the GLP-1 drug albenatide were type 2 diabetes and did not involve obesity indications. “The company has not conducted clinical trials of abenatide for obesity or weight loss. The company has no revenue related to weight loss products.” Changshan Pharmaceutical pointed out. This is the 3rd release by Changshan Pharmaceutical since September about abenatide
It surged 8% after the mid-term report! Beauty is changing, why is Rosalea always the supremacy | Insight Research
To sum up the beauty industry this year, the word “differentiation” is the most appropriate. On August 29, Perraya handed over a semi-annual report that exceeded market expectations, and the stock price surged by more than 8% the next day. This certainly sends a positive signal to the market: high-quality beauty brands can maintain strong growth in the face of change. However, the market also needs to clearly see that the days of relying on marketing and big promotions to stimulate sales are over. When consumption returns to rationality, domestic cosmetics must also show some “real skills.” Direct sales account for a high share — costs are lower and prices are more manageable. Looking at a single quarter, Perrayal's revenue and net profit grew rapidly in the second quarter.
The impact of the epidemic on Bethany, the income growth rate in the first half of the year, and the unit record for the amount reported in the interim report is questionable as “oolong”?
Multi-brand strategy
Medical beauty earns 200 million dollars a month and has to participate in the internal volume of diet pills. Where is the boundary of America's ambition?
It's not easy to take diet pills
Review of December 24: full momentum this week, release the volume of the main funds to attack 5 shares next week.
December 24 news, the three major indices opened low, and then Prev maintained a low consolidation, the gem index led two cities down. In terms of the plate, medicine-related plates collectively rose, Chinese medicine stocks led the rise, food processing, retail and other consumer stocks were active against the trend; lithium batteries, photovoltaic, energy storage and other new energy tracks fell across the board, of which the weight fell more than 9% in the Ningde era. The index continued to weaken in the afternoon, with the gem index falling 2.7% at one point. Cultivate diamond, NFT concept stocks pull up; automobile, rare earth, fluorine chemical industry, digital currency and other sectors in the doldrums. Overall, market sentiment cooled, individual stocks showed a general downward trend, the two markets
China Resources Sanjiu Logs Higher Net Profit, Revenue in January-September; Shares Slump 10%
03:06 AM EDT, 10/27/2021 (MT Newswires) -- China Resources Sanjiu Medical & Pharmaceutical (SHE:000999) posted a net profit of 1.76 billion yuan ($275.7 million) in the nine months ended Sept. 30
Wushi: 15 institutions, including Zhongtai Securities and Jinyou Chuangzhi, investigated our company on September 24.
I Wu Bio (300357) issued an announcement on September 26th, 2021: Zhang Nan of Zhongtai Securities, Jinyou Chuangzhi Li Ning Co. Ltd., Zhang Zhicong, alluvial assets Zhang Zhicong, Huanyi assets Changxintong, Wang Yi of Guodu Securities, Ding Zhiyuan of Yangtze River Pension, Deng Ke of Jiupeng assets, Zhou Chun of Chunda Fund. Ma Dongdong, Guangfa Capital Manager Xu Mofan, Pengyang Fund Yan Dingan, Donghai Securities Asset Management Sui Xin, Tianzhi Fund Wang Yikun, Caitong Fund Zhang Yin, Dan Yi Investment Han Dengke, Zhejiang Merchant Capital Manager Jin Yan investigated our company on September 24, 2021. The survey was received by Guan Zhenwei, Deputy General Manager and Secretary of the Board of Directors, and Tong Jinling, Director of Investor Relations. This adjustment
11 companies, including Zhonglai shares and Jinpu Titanium Industry, announced bad news on September 24.
1. Zhonglai shares: shareholders intend to reduce no more than 6% of the company's shares Zhonglai shares announcement, shareholders Taizhou Jiangyan de new material equity investment partnership intends to reduce no more than 6% of the company's shares. two。 Jiakai City: shareholders intend to reduce their holdings of no more than 1% of the company's shares, Jiakai City announcement. The National University Group, which holds 6.58% of the shares, and its concerted actor, Zheshang Sugar and Liquor, plan to reduce their holdings of no more than 36 million shares in the company by centralized bidding within 6 months after 15 trading days. that is, no more than 1% of the total share capital. 3. Aerospace engineering: shareholders intend to reduce their shares in the company by no more than 1%. Aerospace engineering announcement, shareholders move.
Read Huaxi Biology 2021 China News in one picture
According to the Securities Star data Center, Huaxi Biological 2021 reported that the company's main income was 1.937 billion yuan, up 104.44% from the same period last year; the net profit from its parent was 361 million yuan, up 35.01% from the same period last year; deducting 306 million yuan from non-net profit, up 30.68% from the same period last year; debt ratio 20.03%, investment income 21.2031 million yuan, financial expenses 4.0533 million yuan, gross profit margin 77.91%. There are three new shareholders in this period, J.P. MorganSecuritiesPLC-804211 shares held by its own funds, accounting for the proportion of outstanding shares.
Zhong Cang Wanhua Chemical made a huge profit of more than 5 billion Niusan, and now he is doing it again!
Retail investors account for the largest number of investors in A-shares, with data showing that by the end of August 2021, the number of A-share investors had reached 192 million, of which more than 99 per cent were natural persons, also known as retail investors. Compared with institutions, retail investors have a relatively low level of investment. However, because of the large number, many retail investors are also born a lot of cattle scattered, that is, a high level of technology, a huge position of the natural person. When it comes to scattered, we have to mention Sun Huigang, who became famous because of his heavy position of CRRC Corporation, and later made a huge profit of more than 5 billion because of Chong Cang Wanhua Chemical Co., Ltd. Recently, he once again aroused widespread concern in the market.
On September 16, six companies announced positive results: Angel Yeast plans to establish a joint venture with Neubao Foods to develop the baby snack food business
Yutong Technology announced that it plans to spend 100 million to 200 million yuan to repurchase shares of Yutong Technology. The company plans to repurchase the company's shares at a price of no more than 41.19 yuan/share, with a repurchase amount of not less than 10 million yuan and no more than 20 million yuan. All of the shares repurchased will be used for employee stock ownership plans or equity incentive plans. Angel Yeast announced that it plans to establish a joint venture with Neubao Foods to develop the baby snack food business Angel Yeast. In order to promote the rapid development of the baby snack food business segment, Angel Yeast plans to establish a joint venture with Kang Helong, Hubei Neubao Food Technology Co., Ltd. (with industry and commerce)
On September 15, 10 companies including Angel Yeast and Yan'an Bikang announced favorable results
1. Angel Yeast: Angel Yeast announced that it intends to establish a joint venture with Kang Helong to develop the baby snack food business. In order to promote the rapid development of the baby snack food business segment, Angel News plans to establish a joint venture with Kang Helong. The joint venture will seek new opportunities for development in the field of infant snack food as a holding subsidiary specializing in the development of products related to the snack food industry by Angel Newt. 2. Poinsettia: The wholly-owned subsidiary obtained the bromhexine hydrochloride injection registration certificate. The wholly-owned subsidiary obtained the bromhexine hydrochloride injection registration certificate. 3. Qianjing Garden: Won the bid 67
Sept. 8 Taian Tang trading analysis: Internet health care, assisted reproduction, traditional Chinese medicine concept hot stocks
Securities Star data Center News, Taian Tang rose the limit to close, closing price 6.22 yuan. The stock rose by the limit at 09:47 and opened once, with a closing fund of 35.4148 million yuan, accounting for 0.76% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 79.9379 million yuan, the net inflow of hot capital was 86.2267 million yuan, and the net outflow of retail funds was 37.4142 million yuan. The flow of funds in the past five days is shown in the following table: this unit is a hot stock of Internet medical care, assisted reproduction and traditional Chinese medicine concept. On the same day, the Internet medical concept rose 1.12%, and the concept of assisted reproduction rose 0.6%.
Guang Yuanyuan impact two consecutive trading limit, investors are expected to lift the trap?
Guang Yuyuan, once a traditional Chinese medicine "demon stock", has finally ushered in a rising momentum after a substantial adjustment, and continues to hit the limit today after yesterday's limit. It can be said that the stock price, which is well-known for its two major concepts, has experienced a roller coaster in recent months. For its hype, it began with the difficulty of finding a tablet of Pian Tsai Yi, and then Yunnan Baiyao was also hyped, and then the market began to look for relatively undervalued stocks of traditional Chinese medicine, and the wide reputation was speculated by funds under this background. Similar to the top secret formula of Yunnan Baiyao and pianzi, Guangyuanyuan also has the age of turtles.
Eight IPOs this week saw another “meat signature”. One signing may earn 50,000 yuan
According to the preliminary arrangement, if there are no changes, the A-share market will welcome 8 new shares to be purchased this week (September 6 to September 10), including 2 on the Science and Technology Innovation Board, 4 on the GEM board, and 1 each on the Shanghai and Shenzhen main boards. Specifically, there are 3 new shares on Monday, 2 new shares on Tuesday, 2 new shares on Wednesday, and 1 new stock on Thursday. Judging from the industry distribution, this IPO involves popular environmental protection and industrial motherboards in the current market. It is worth mentioning that 4 of next week's IPOs will require less than 100,000 yuan in market capitalization to reach the top. They are Zhuojin shares, the new stock of the Science and Technology Innovation Board, the IPO shares of Zhonglan Environmental Protection, Sea Pot shares, and Mastery
Copy homework! These 10 shares are highly sought after by private equity! Which stocks did Feng Liu, Deng Xiaofeng, and Ge Weidong hold more than 60 billion dollars?
As the interim reports came to an end one after another, the latest holdings of many private equity bosses also gradually surfaced. By August 30, 1,633 private equity products had appeared in the list of the top ten tradable shareholders of listed companies. According to public data, with a market capitalization of 54 billion yuan, Gao Yi is far ahead. According to media statistics, Zijin Mining, Sany Heavy Industries, Yonghui Supermarket, Western Superconductor, Tianshan Aluminum, Huayou Cobalt, Wanda Film, Huarui 39, Hengli Hydraulic, and Sunwanda were the 10 largest new private equity markets in the second quarter. Meanwhile, the top ten largest private equity stocks were Maotai, Hikvision, Zijin Mining, and Ziguang Guowei, respectively
Medical beauty is also subject to strict supervision, the State Drug Administration: will focus on strengthening the management of this kind of medical beauty products
Since the beginning of this year, the state has carried out rectification on the chaos in the medical and beauty industry, and the medical and beauty industry has also ushered in the strictest supervision. Since the previous eight ministries'"Special rectification work Plan for cracking down on illegal Medical Beauty Services", relevant regulatory policies have been issued one after another, from medical beauty products to medical beauty institutions, from medical beauty financial services to medical beauty advertising, gradually forming a systematic supervision model. Today, the supervision of medical care and beauty has been added to the weight. The official website of the State Drug Administration announced on September 1 that it will focus on strengthening the management of products such as plastic plastic injection fillers and phototherapy cosmetic equipment. And remind operating enterprises and users to purchase from legal channels to obtain registration certificates or prepare according to law.